Gene · 369
Papers2,279
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,279
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. | Mol Biomed | 2022 | 36539659 | PubTator, text mining | PubMed |
| Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis. | Cell Commun Signal | 2022 | 36536400 | PubTator, text mining | PubMed |
| New prospectives on treatment opportunities in RASopathies. | Am J Med Genet C Semin Med Genet | 2022 | 36533679 | PubTator, text mining | PubMed |
| Biomarkers in the development of individualized treatment regimens for colorectal cancer. | Front Med (Lausanne) | 2022 | 36530921 | PubTator, text mining | PubMed |
| Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer. | BMC Cancer | 2022 | 36522653 | PubTator, text mining | PubMed |
| Case report: Cerebrospinal fluid-derived circulating tumor DNA diagnoses and guides the treatment of a lung adenocarcinoma case with leptomeningeal metastasis. | Front Oncol | 2022 | 36518317 | PubTator, text mining | PubMed |
| Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein. | Molecules | 2022 | 36500607 | PubTator, text mining | PubMed |
| Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. | Int J Mol Sci | 2022 | 36499382 | PubTator, text mining | PubMed |
| Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma. | Cancers (Basel) | 2022 | 36497337 | PubTator, text mining | PubMed |
| Predicting chemical structure using reinforcement learning with a stack-augmented conditional variational autoencoder. | J Cheminform | 2022 | 36494855 | PubTator, text mining | PubMed |
| Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL-variant. | EJHaem | 2022 | 36467805 | PubTator, text mining | PubMed |
| Current concepts of anti-EGFR targeting in metastatic colorectal cancer. | Front Oncol | 2022 | 36465407 | PubTator, text mining | PubMed |
| Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells. | BMC Cancer | 2022 | 36460969 | PubTator, text mining | PubMed |
| Construction and validation of a novel and superior protein risk model for prognosis prediction in esophageal cancer. | Front Genet | 2022 | 36457747 | PubTator, text mining | PubMed |
| Genomic characterization of intracranial teratomas using whole genome sequencing. | Front Oncol | 2022 | 36457486 | PubTator, text mining | PubMed |
| Targeting the FGF/FGFR axis and its co-alteration allies. | ESMO Open | 2022 | 36455506 | PubTator, text mining | PubMed |
| Remodeling tumor microenvironment with natural products to overcome drug resistance. | Front Immunol | 2022 | 36439106 | PubTator, text mining | PubMed |
| BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy. | Nat Commun | 2022 | 36402789 | Swiss-Prot, curated | PubMed |
| RASopathy mutations open new insights into the mechanism of BRAF activation. | Mol Cell | 2022 | 36400004 | PubTator, text mining | PubMed |
| Ubiquitin-assisted phase separation of dishevelled-2 promotes Wnt signalling. | J Cell Sci | 2022 | 36398662 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/papers?page=17